Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 3016 entries
Sorted by: Best Match Show Resources per page
Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease.

International journal of clinical and experimental medicine

Wang Z, Song HY, An MM, Zhu LL.
PMID: 26770566
Int J Clin Exp Med. 2015 Oct 15;8(10):19290-6. eCollection 2015.

OBJECTIVE: To investigate the association of serum SPARC level with the severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease.METHODS: 120 patients with type 2 diabetic patients were the subjects. Enzyme-linked immunosorbent assay (ELISA)...

Cite
Wang Z, Song HY, An MM, et al. Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. Int J Clin Exp Med. 2015;8(10):19290-6
Wang, Z., Song, H. Y., An, M. M., & Zhu, L. L. (2015). Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. International journal of clinical and experimental medicine, 8(10), 19290-6.
Wang, Zheng, et al. "Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease." International journal of clinical and experimental medicine vol. 8,10 (2015): 19290-6.
Wang Z, Song HY, An MM, Zhu LL. Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. Int J Clin Exp Med. 2015 Oct 15;8(10):19290-6. eCollection 2015. PMID: 26770566; PMCID: PMC4694466.
Copy Download .nbib Format: NLM
Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901.

OncoTargets and therapy

Liu T, Ye YW, Zhu AL, Yang Z, Fu Y, Wei CQ, Liu Q, Zhao CL, Wang GJ, Zhang XF.
PMID: 26064061
Onco Targets Ther. 2015 May 27;8:1265-70. doi: 10.2147/OTT.S78514. eCollection 2015.

This study was designed to investigate the proliferation inhibition and apoptosis-promoting effect under hyperthermia and chemotherapy treatment, at cellular level. Human gastric cancer cell line SGC-7901 was cultivated with 5-fluorouracil at different temperatures. Cell proliferation and apoptosis were determined,...

Cite
Liu T, Ye YW, Zhu AL, et al. Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901. Onco Targets Ther. 2015;8:1265-70doi: 10.2147/OTT.S78514.
Liu, T., Ye, Y. W., Zhu, A. L., Yang, Z., Fu, Y., Wei, C. Q., Liu, Q., Zhao, C. L., Wang, G. J., & Zhang, X. F. (2015). Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901. OncoTargets and therapy, 81265-70. https://doi.org/10.2147/OTT.S78514
Liu, Tao, et al. "Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901." OncoTargets and therapy vol. 8 (2015): 1265-70. doi: https://doi.org/10.2147/OTT.S78514
Liu T, Ye YW, Zhu AL, Yang Z, Fu Y, Wei CQ, Liu Q, Zhao CL, Wang GJ, Zhang XF. Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901. Onco Targets Ther. 2015 May 27;8:1265-70. doi: 10.2147/OTT.S78514. eCollection 2015. PMID: 26064061; PMCID: PMC4455869.
Copy Download .nbib Format: NLM
Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis.

Cell & bioscience

Peng B, Shi R, Jiang W, Ding YH, Dong MQ, Zhu WG, Xu X.
PMID: 28344766
Cell Biosci. 2017 Mar 23;7:15. doi: 10.1186/s13578-017-0142-x. eCollection 2017.

BACKGROUND: Lysine-specific histone demethylase 1 (LSD1) modulates chromatin status through demethylation of H3K4 and H3K9. It has been demonstrated that LSD1 is hyperphosphorylated and dissociates from chromatin during mitosis. However, the molecular mechanism of LSD1 detachment is unknown.RESULTS: In...

Cite
Peng B, Shi R, Jiang W, et al. Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis. Cell Biosci. 2017;7:15doi: 10.1186/s13578-017-0142-x.
Peng, B., Shi, R., Jiang, W., Ding, Y. H., Dong, M. Q., Zhu, W. G., & Xu, X. (2017). Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis. Cell & bioscience, 715. https://doi.org/10.1186/s13578-017-0142-x
Peng, Bin, et al. "Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis." Cell & bioscience vol. 7 (2017): 15. doi: https://doi.org/10.1186/s13578-017-0142-x
Peng B, Shi R, Jiang W, Ding YH, Dong MQ, Zhu WG, Xu X. Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis. Cell Biosci. 2017 Mar 23;7:15. doi: 10.1186/s13578-017-0142-x. eCollection 2017. PMID: 28344766; PMCID: PMC5364692.
Copy Download .nbib Format: NLM
Spectral karyotyping reveals a comprehensive karyotype in an adult acute lymphoblastic leukemia.

EXCLI journal

Guo B, Zhu HL, Li SX, Lu XC, Fan H, Da WM.
PMID: 27298606
EXCLI J. 2012 Mar 01;11:89-92. eCollection 2012.

Cytogenetic abnormalities are frequently detected in patients with acute lymphoblastic leukemia (ALL). Comprehensive karyotype was related to poor prognosis frequently in ALL. We present a comprehensive karyotype in an adult ALL by spectral karyotyping (SKY) and R-banding. SKY not...

Cite
Guo B, Zhu HL, Li SX, et al. Spectral karyotyping reveals a comprehensive karyotype in an adult acute lymphoblastic leukemia. EXCLI J. 2012;11:89-92
Guo, B., Zhu, H. L., Li, S. X., Lu, X. C., Fan, H., & Da, W. M. (2012). Spectral karyotyping reveals a comprehensive karyotype in an adult acute lymphoblastic leukemia. EXCLI journal, 1189-92.
Guo, Bo, et al. "Spectral karyotyping reveals a comprehensive karyotype in an adult acute lymphoblastic leukemia." EXCLI journal vol. 11 (2012): 89-92.
Guo B, Zhu HL, Li SX, Lu XC, Fan H, Da WM. Spectral karyotyping reveals a comprehensive karyotype in an adult acute lymphoblastic leukemia. EXCLI J. 2012 Mar 01;11:89-92. eCollection 2012. PMID: 27298606; PMCID: PMC4897657.
Copy Download .nbib Format: NLM
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Therapeutics and clinical risk management

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q.
PMID: 25848291
Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015.

BACKGROUND: Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may...

Cite
Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449-67doi: 10.2147/TCRM.S80437.
Wang, Z. Y., Chen, M., Zhu, L. L., Yu, L. S., Zeng, S., Xiang, M. X., & Zhou, Q. (2015). Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and clinical risk management, 11449-67. https://doi.org/10.2147/TCRM.S80437
Wang, Zhi-Yu, et al. "Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy." Therapeutics and clinical risk management vol. 11 (2015): 449-67. doi: https://doi.org/10.2147/TCRM.S80437
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015. PMID: 25848291; PMCID: PMC4373598.
Copy Download .nbib Format: NLM
Recombinant nanocomposites by the clinical drugs of Abraxane.

Journal of Cancer

Ding S, Xiong J, Lei D, Zhu XL, Zhang HJ.
PMID: 29483955
J Cancer. 2018 Jan 01;9(3):502-511. doi: 10.7150/jca.22163. eCollection 2018.

Breast cancer greatly threatens the health of women all over the word despite of several effective drugs. Targeted therapy for breast cancer is limited to human epidermal growth factor receptor 2 (HER2). Herceptin

Cite
Ding S, Xiong J, Lei D, et al. Recombinant nanocomposites by the clinical drugs of Abraxane. J Cancer. 2018;9(3):502-511doi: 10.7150/jca.22163.
Ding, S., Xiong, J., Lei, D., Zhu, X. L., & Zhang, H. J. (2018). Recombinant nanocomposites by the clinical drugs of Abraxane. Journal of Cancer, 9(3), 502-511. https://doi.org/10.7150/jca.22163
Ding, Shuang, et al. "Recombinant nanocomposites by the clinical drugs of Abraxane." Journal of Cancer vol. 9,3 (2018): 502-511. doi: https://doi.org/10.7150/jca.22163
Ding S, Xiong J, Lei D, Zhu XL, Zhang HJ. Recombinant nanocomposites by the clinical drugs of Abraxane. J Cancer. 2018 Jan 01;9(3):502-511. doi: 10.7150/jca.22163. eCollection 2018. PMID: 29483955; PMCID: PMC5820917.
Copy Download .nbib Format: NLM
Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.

Oncotarget

Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X.
PMID: 29069819
Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22.

We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled...

Cite
Wang SL, Dong WB, Dong XL, et al. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017;8(42):72700-72713doi: 10.18632/oncotarget.20282.
Wang, S. L., Dong, W. B., Dong, X. L., Zhu, W. M., Wang, F. F., Han, F., & Yan, X. (2017). Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget, 8(42), 72700-72713. https://doi.org/10.18632/oncotarget.20282
Wang, Shao-Lian, et al. "Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus." Oncotarget vol. 8,42 (2017): 72700-72713. doi: https://doi.org/10.18632/oncotarget.20282
Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22. PMID: 29069819; PMCID: PMC5641162.
Copy Download .nbib Format: NLM
[No title available]

Oncotarget

Ma J, Zhu SL, Liu Y, Huang XY, Su DK.
PMID: 29069838
Oncotarget. 2017 Jun 16;8(42):72939-72949. doi: 10.18632/oncotarget.18513. eCollection 2017 Sep 22.

This study aimed to investigate the association of the

Cite
Ma J, Zhu SL, Liu Y, et al. . Oncotarget. 2017;8(42):72939-72949doi: 10.18632/oncotarget.18513.
Ma, J., Zhu, S. L., Liu, Y., Huang, X. Y., & Su, D. K. (2017). . Oncotarget, 8(42), 72939-72949. https://doi.org/10.18632/oncotarget.18513
Ma, Jie, et al. "." Oncotarget vol. 8,42 (2017): 72939-72949. doi: https://doi.org/10.18632/oncotarget.18513
Ma J, Zhu SL, Liu Y, Huang XY, Su DK. . Oncotarget. 2017 Jun 16;8(42):72939-72949. doi: 10.18632/oncotarget.18513. eCollection 2017 Sep 22. PMID: 29069838; PMCID: PMC5641181.
Copy Download .nbib Format: NLM
Molecular Engineering of Pyrido[3,4-b]pyrazine-Based Donor-Acceptor-π-Acceptor Organic Sensitizers: Effect of Auxiliary Acceptor in Cobalt- and Iodine-Based Electrolytes.

Chemistry (Weinheim an der Bergstrasse, Germany)

Liu B, Giordano F, Pei K, Decoppet JD, Zhu WH, Zakeeruddin SM, Grätzel M.
PMID: 26548926
Chemistry. 2015 Dec 14;21(51):18654-61. doi: 10.1002/chem.201503514. Epub 2015 Nov 09.

Due to the ease of tuning its redox potential, the cobalt-based redox couple has been extensively applied for highly efficient dye-sensitized solar cells (DSSCs) with extraordinarily high photovoltages. However, a cobalt electrolyte needs particular structural changes in the organic...

Cite
Liu B, Giordano F, Pei K, et al. Molecular Engineering of Pyrido[3,4-b]pyrazine-Based Donor-Acceptor-π-Acceptor Organic Sensitizers: Effect of Auxiliary Acceptor in Cobalt- and Iodine-Based Electrolytes. Chemistry. 2015;21(51):18654-61doi: 10.1002/chem.201503514.
Liu, B., Giordano, F., Pei, K., Decoppet, J. D., Zhu, W. H., Zakeeruddin, S. M., & Grätzel, M. (2015). Molecular Engineering of Pyrido[3,4-b]pyrazine-Based Donor-Acceptor-π-Acceptor Organic Sensitizers: Effect of Auxiliary Acceptor in Cobalt- and Iodine-Based Electrolytes. Chemistry (Weinheim an der Bergstrasse, Germany), 21(51), 18654-61. https://doi.org/10.1002/chem.201503514
Liu, Bo, et al. "Molecular Engineering of Pyrido[3,4-b]pyrazine-Based Donor-Acceptor-π-Acceptor Organic Sensitizers: Effect of Auxiliary Acceptor in Cobalt- and Iodine-Based Electrolytes." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 21,51 (2015): 18654-61. doi: https://doi.org/10.1002/chem.201503514
Liu B, Giordano F, Pei K, Decoppet JD, Zhu WH, Zakeeruddin SM, Grätzel M. Molecular Engineering of Pyrido[3,4-b]pyrazine-Based Donor-Acceptor-π-Acceptor Organic Sensitizers: Effect of Auxiliary Acceptor in Cobalt- and Iodine-Based Electrolytes. Chemistry. 2015 Dec 14;21(51):18654-61. doi: 10.1002/chem.201503514. Epub 2015 Nov 09. PMID: 26548926.
Copy Download .nbib Format: NLM
Inguinal Hernia: Lap vs Open.

Hernia : the journal of hernias and abdominal wall surgery

Vassiliadis A, Zanoni A, Di Leo A, Zanella S, Lauro E, Moscatelli P, Ricci F, Huang H, Wada N, Furukawa T, Kitagawa Y, Hirukawa H, Takesue Y, Saito K, Sato H, Tada T, Choua O, Fu XJ, Yao QY, Yang S, Wang MG, Zhu YL, Cao JX, Shen YM, Togbe JO, Gbessi DG, Dossou FM, Iawani I, Cijan V, Gencic M, Scepanovic M, Bojovic P, Brankovic M, Agresta F, Verza LA, Prando D, Roveran MA, Azabdaftari A, Rubinato L, Vacca U, Lubrano T, Vidotto C, Falcone A, Grasso L, Ghiglione F, Morino M, Nácul M, Cavazzola L, Loureiro M, Bonin E, Ferreira P, Misra MC, Bansal VK, Subodh K, Krisha A, Bansal D, Ray S, Rajeshwari S, Wang P, Jia Z, Zhang FJ, Yan JJ, Zhu YH, Jiang K, Altinli E, Eroglu E, Sertel HI, Hizli F, Jacob B, Bresnaham E, Reiner M, Bates A.
PMID: 26518862
Hernia. 2015 Apr;19:S57-62. doi: 10.1007/BF03355327.

No abstract available.

Cite
Vassiliadis A, Zanoni A, Di Leo A, et al. Inguinal Hernia: Lap vs Open. Hernia. 2015;19:S57-62doi: 10.1007/BF03355327.
Vassiliadis, A., Zanoni, A., Di Leo, A., Zanella, S., Lauro, E., Moscatelli, P., Ricci, F., Huang, H., Wada, N., Furukawa, T., Kitagawa, Y., Hirukawa, H., Takesue, Y., Saito, K., Sato, H., Tada, T., Choua, O., Fu, X. J., Yao, Q. Y., Yang, S., Wang, M. G., Zhu, Y. L., Cao, J. X., Shen, Y. M., Togbe, J. O., Gbessi, D. G., Dossou, F. M., Iawani, I., Cijan, V., Gencic, M., Scepanovic, M., Bojovic, P., Brankovic, M., Agresta, F., Verza, L. A., Prando, D., Roveran, M. A., Azabdaftari, A., Rubinato, L., Vacca, U., Lubrano, T., Vidotto, C., Falcone, A., Grasso, L., Ghiglione, F., Morino, M., Nácul, M., Cavazzola, L., Loureiro, M., Bonin, E., Ferreira, P., Misra, M. C., Bansal, V. K., Subodh, K., Krisha, A., Bansal, D., Ray, S., Rajeshwari, S., Wang, P., Jia, Z., Zhang, F. J., Yan, J. J., Zhu, Y. H., Jiang, K., Altinli, E., Eroglu, E., Sertel, H. I., Hizli, F., Jacob, B., Bresnaham, E., Reiner, M., & Bates, A. (2015). Inguinal Hernia: Lap vs Open. Hernia : the journal of hernias and abdominal wall surgery, 19S57-62. https://doi.org/10.1007/BF03355327
Vassiliadis, A, et al. "Inguinal Hernia: Lap vs Open." Hernia : the journal of hernias and abdominal wall surgery vol. 19 (2015): S57-62. doi: https://doi.org/10.1007/BF03355327
Vassiliadis A, Zanoni A, Di Leo A, Zanella S, Lauro E, Moscatelli P, Ricci F, Huang H, Wada N, Furukawa T, Kitagawa Y, Hirukawa H, Takesue Y, Saito K, Sato H, Tada T, Choua O, Fu XJ, Yao QY, Yang S, Wang MG, Zhu YL, Cao JX, Shen YM, Togbe JO, Gbessi DG, Dossou FM, Iawani I, Cijan V, Gencic M, Scepanovic M, Bojovic P, Brankovic M, Agresta F, Verza LA, Prando D, Roveran MA, Azabdaftari A, Rubinato L, Vacca U, Lubrano T, Vidotto C, Falcone A, Grasso L, Ghiglione F, Morino M, Nácul M, Cavazzola L, Loureiro M, Bonin E, Ferreira P, Misra MC, Bansal VK, Subodh K, Krisha A, Bansal D, Ray S, Rajeshwari S, Wang P, Jia Z, Zhang FJ, Yan JJ, Zhu YH, Jiang K, Altinli E, Eroglu E, Sertel HI, Hizli F, Jacob B, Bresnaham E, Reiner M, Bates A. Inguinal Hernia: Lap vs Open. Hernia. 2015 Apr;19:S57-62. doi: 10.1007/BF03355327. PMID: 26518862.
Copy Download .nbib Format: NLM
Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Journal of translational science

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.
PMID: 27076919
J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05.

Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid...

Cite
Ishiguro K, Zhu YL, Lin ZP, et al. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124doi: 10.15761/JTS.1000127.
Ishiguro, K., Zhu, Y. L., Lin, Z. P., Penketh, P. G., Shyam, K., Zhu, R., Baumann, R. P., Sartorelli, A. C., Rutherford, T. J., & Ratner, E. S. (2016). Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. Journal of translational science, 2(2), 117-124. https://doi.org/10.15761/JTS.1000127
Ishiguro, Kimiko, et al. "Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines." Journal of translational science vol. 2,2 (2016): 117-124. doi: https://doi.org/10.15761/JTS.1000127
Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2(2):117-124. doi: 10.15761/JTS.1000127. Epub 2016 Mar 05. PMID: 27076919; PMCID: PMC4827869.
Copy Download .nbib Format: NLM
Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients.

Oncotarget

Wu G, Li MM, Chen F, Lin SM, Yang K, Zhao YM, Zhu XL, Huang WY, Li JJ.
PMID: 29029498
Oncotarget. 2017 Aug 02;8(39):66128-66136. doi: 10.18632/oncotarget.19820. eCollection 2017 Sep 12.

In this prospective study, we analyzed diffusion kurtosis imaging (DKI) parameters to predict the early response to radiotherapy in 23 nasopharyngeal carcinoma (NPC) patients. All patients underwent conventional magnetic resonance imaging (MRI) and DKI before and after radiotherapy. The...

Cite
Wu G, Li MM, Chen F, et al. Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients. Oncotarget. 2017;8(39):66128-66136doi: 10.18632/oncotarget.19820.
Wu, G., Li, M. M., Chen, F., Lin, S. M., Yang, K., Zhao, Y. M., Zhu, X. L., Huang, W. Y., & Li, J. J. (2017). Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients. Oncotarget, 8(39), 66128-66136. https://doi.org/10.18632/oncotarget.19820
Wu, Gang, et al. "Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients." Oncotarget vol. 8,39 (2017): 66128-66136. doi: https://doi.org/10.18632/oncotarget.19820
Wu G, Li MM, Chen F, Lin SM, Yang K, Zhao YM, Zhu XL, Huang WY, Li JJ. Diffusion-kurtosis imaging predicts early radiotherapy response in nasopharyngeal carcinoma patients. Oncotarget. 2017 Aug 02;8(39):66128-66136. doi: 10.18632/oncotarget.19820. eCollection 2017 Sep 12. PMID: 29029498; PMCID: PMC5630398.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 3016 entries